Edition:
United Kingdom

Axsome Therapeutics Inc (AXSM.OQ)

AXSM.OQ on NASDAQ Stock Exchange Global Market

3.15USD
20 Jul 2018
Change (% chg)

$0.05 (+1.61%)
Prev Close
$3.10
Open
$3.10
Day's High
$3.20
Day's Low
$3.10
Volume
8,409
Avg. Vol
33,475
52-wk High
$6.45
52-wk Low
$2.05

Chart for

About

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02... (more)

Overall

Beta: --
Market Cap(Mil.): $146.39
Shares Outstanding(Mil.): 23.61
Dividend: --
Yield (%): --

Financials

  AXSM.OQ Industry Sector
P/E (TTM): -- 85.33 32.76
EPS (TTM): -1.47 -- --
ROI: -90.07 2.22 14.61
ROE: -102.68 3.86 16.34

BRIEF-Axsome Therapeutics Reports Q1 Loss Per Share Of $0.19

* AXSOME THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

08 May 2018

BRIEF-Axsome Therapeutics Announces First Patient Enrolled In Phase 2 Clinical Trial Of AXS-05 In Smoking Cessation

* AXSOME THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL OF AXS-05 IN SMOKING CESSATION Source text for Eikon: Further company coverage:

23 Apr 2018

BRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer

* AXSOME THERAPEUTICS APPOINTS NICK PIZZIE, CPA, MBA, AS CHIEF FINANCIAL OFFICER

19 Apr 2018

BRIEF-Axsome Therapeutics Reports Q4 Loss Per Share $0.31

* AXSOME THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

07 Mar 2018

BRIEF-Axsome Therapeutics Says Its CNS Disorder Candidate AXS-09 Met Main Goal Of Phase 1 Trial

* AXSOME THERAPEUTICS ANNOUNCES PRIMARY ENDPOINT MET IN PHASE 1 TRIAL OF NEXT GENERATION PRODUCT CANDIDATE AXS-09 CONTAINING CHIRALLY PURE ESBUPROPION AND DEXTROMETHORPHAN

26 Feb 2018

Earnings vs. Estimates